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ORIGINAL ARTICLE

Optimal duration of risperidone or olanzapine adjunctive
therapy to mood stabilizer following remission of a manic
episode: A CANMAT randomized double-blind trial
LN Yatham1, S Beaulieu2, A Schaffer3, M Kauer-Sant’Anna4, F Kapczinski4, B Lafer5, V Sharma6, SV Parikh7, A Daigneault8, H Qian9,
DJ Bond1, PH Silverstone10, N Walji1, R Milev11, P Baruch12, A da Cunha13, J Quevedo14, R Dias5, M Kunz4, LT Young15, RW Lam1 and
H Wong16
Atypical antipsychotic adjunctive therapy to lithium or valproate is effective in treating acute mania. Although continuation of
atypical antipsychotic adjunctive therapy after mania remission reduces relapse of mood episodes, the optimal duration is
unknown. As many atypical antipsychotics cause weight gain and metabolic syndrome, they should not be continued unless the
beneﬁts outweigh the risks. This 52-week double-blind placebo-controlled trial recruited patients with bipolar I disorder (n = 159)
who recently remitted from a manic episode during treatment with risperidone or olanzapine adjunctive therapy to lithium or
valproate. Patients were randomized to one of three conditions: discontinuation of risperidone or olanzapine and substitution with
placebo at (i) entry (‘0-weeks’ group) or (ii) at 24 weeks after entry (‘24-weeks’ group) or (iii) continuation of risperidone or
olanzapine for the full duration of the study (‘52-weeks’ group). The primary outcome measure was time to relapse of any mood
episode. Compared with the 0-weeks group, the time to any mood episode was signiﬁcantly longer in the 24-weeks group (hazard
ratio (HR) 0.53; 95% conﬁdence interval (CI): 0.33, 0.86) and nearly so in the 52-weeks group (HR: 0.63; 95% CI: 0.39, 1.02). The
relapse rate was similar in the 52-weeks group compared with the 24-weeks group (HR: 1.18; 95% CI: 0.71, 1.99); however, subgroup analysis showed discordant results between the two antipsychotics (HR: 0.48, 95% CI: 0.17; 1.32 olanzapine patients; HR: 1.85,
95% CI: 1.00, 3.41 risperidone patients). Average weight gain was 3.2 kg in the 52-weeks group compared with a weight loss of
0.2 kg in the 0-weeks and 0.1 kg in the 24-weeks groups. These ﬁndings suggest that risperidone or olanzapine adjunctive therapy
for 24 weeks is beneﬁcial but continuation of risperidone beyond this period does not reduce the risk of relapse. Whether
continuation of olanzapine beyond this period reduces relapse risk remains unclear but the potential beneﬁt needs to be weighed
against an increased risk of weight gain.
Molecular Psychiatry (2016) 21, 1050–1056; doi:10.1038/mp.2015.158; published online 13 October 2015

INTRODUCTION
Bipolar I disorder is a lifelong condition characterized by manic
and depressive episodes. A signiﬁcant proportion of patients
experiencing an acute manic episode are treated with a
combination of a mood stabilizer (that is, lithium or valproate)
and an atypical antipsychotic.1,2 There is general consensus as
indicated by recommendations from various guidelines about
continuing a mood stabilizer to reduce the risk of relapse or
recurrence of a mood episode.3–5 In addition, there is also
evidence from some6–9 but not all10 studies that continuation of
an atypical antipsychotic as an adjunct to a mood stabilizer
provides additional beneﬁt in reducing the risk of relapse but the

optimal duration of such strategy remains unknown. For instance,
different industry-funded registration trials have reported
continuation of an atypical antipsychotic as being beneﬁcial,
compared with placebo, when given as adjunct for 6 months,9 12
months8 or 24 months.6,7 However, none of these studies
examined different durations for the atypical antipsychotic
therapy within the same trial. An examination of survival curves
from these trials suggests that most relapses in the placebo
adjunctive therapy group occurred within the ﬁrst 6 months of
randomization. Does this mean that the atypical antipsychotic
adjunctive therapy is beneﬁcial mainly within the ﬁrst 6 months of
remission of an acute mood episode and not beyond? This is a
critical question because atypical antipsychotics are associated
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with signiﬁcant side effects such as weight gain, metabolic
syndrome and extrapyramidal side effects and hence should not
be continued unless their beneﬁts beyond 6 months can be clearly
demonstrated.
Therefore, the primary objective of this randomized doubleblind placebo-controlled trial was to determine the efﬁcacy of
different durations (24 or 52 weeks) of atypical antipsychotic
adjunctive therapy (that is, risperidone or olanzapine) to mood
stabilizer vs discontinuing the atypical antipsychotic at study entry
in preventing relapse of any mood episode in bipolar I disorder
patients who recently remitted (within 6 weeks of remission) from
an acute manic episode. An important additional objective was to
investigate whether 52 weeks of treatment offered any additional
beneﬁt compared with discontinuing the atypical antipsychotic
after 24 weeks.
MATERIALS AND METHODS
Subjects
Patients for the study were recruited from 17 Canadian Network for Mood
and Anxiety Treatments (CANMAT)-afﬁliated academic centers in Canada
and collaborating sites in Brazil. Study procedures were approved by the
Research Ethics Boards of each site. A written informed consent was
obtained from all patients after providing a complete description of the
study. Patients aged ⩾ 17 years were eligible for the study if they were:
(1) diagnosed with Bipolar I disorder; (2) treated within the previous
12 weeks, for a DSM-IV11 acute manic or mixed episode with a
combination of mood stabilizer (lithium or valproate) and atypical
antipsychotic (risperidone or olanzapine); (3) in remission from the manic
or mixed episode for at least 2 weeks and no more than 6 weeks based on
(i) a Clinical Global Impression Severity (CGI-S)12 score of 2 or less for 2
consecutive weeks or (ii) a Young Mania Rating Scale (YMRS)13 score of 8 or
less and a Hamilton Rating Scale for Depression (HAM-D)14 21- item score
of 8 or less for two consecutive weeks.
Patients with a history of comorbid substance abuse or other axis I
disorders were allowed but those taking other psychotropic medication
with the exception of benzodiazepines were excluded.

Trial design and interventions
This study was a multi-center three-parallel-group randomized doubleblind placebo-controlled trial with up to 52 weeks of follow-up. After
obtaining informed consent, patients were randomized to one of the three
groups. Randomizations were stratiﬁed by drug combination and by
center. The treating clinicians and all research personnel except the trial
statistician and the pharmacist were blinded to treatment arm allocations.
Patients randomized to the ‘0-weeks’ group tapered and discontinued
risperidone or olanzapine over 2 weeks beginning on the day of
randomization and received placebo substitution for the remaining
50 weeks. Patients randomized to the ‘24-weeks’ group received
risperidone or olanzapine for 24 weeks. The antipsychotic was tapered
and discontinued over the next 2 weeks with the placebo substitution for
the remaining 26 weeks. Patients randomized to the ‘52-weeks’ group
continued risperidone or olanzapine for 52 weeks. All patients continued
the same mood stabilizer (lithium or valproate) they had been taking at
study entry and serum levels were maintained within the therapeutic
ranges (0.6–1.2 mmol/L for lithium and 350–830 μmol/L for valproate)
throughout the 52 weeks. The dose and type of atypical antipsychotic were
the same as the patient had been on at entry into the study. Allowed
dosages for risperidone were 1–6 mg per day and olanzapine 5–25 mg
per day. Patients were not allowed to receive any other psychotropic
medication except benzodiazepines for sedation and anti-parkinsonian
medication for extrapyramidal side effects. Patients were allowed to
receive psychoeducation and counseling regarding sleep hygiene, healthy
daily routines and rhythms, alcohol and substance abuse, anxiety
management, conﬂict resolution and problem solving, as clinically
indicated as part of their ongoing clinical care.

Study outcomes
Patients were assessed biweekly until week 8 and every 4 weeks thereafter
up to week 52 by trained raters blind to treatment allocation using the
following instruments: YMRS, HAMD-21, Montgomery-Asberg Depression
© 2016 Macmillan Publishers Limited

Rating Scale (MADRS),15 CGI-S and Clinical Global Impression-Bipolar
Severity (CGI-BP). Clinical Global Impression-Improvement (CGI-I) and
CGI-BP change were assessed from week 2 onwards. Safety and tolerability
were evaluated through clinical observation as well as using the Udvalg for
Kliniske Undersøgelser Side Effect Rating Scale (UKU)16 as well as the
Extrapyramidal Symptoms Rating Scale (ESRS)17 at baseline and at monthly
visits. Laboratory measurements on blood sera were obtained at the
screening visit and at weeks 12, 24, 36 and 52.
The primary outcome measure was the time to any mood episode,
deﬁned as any of the following events: (i) YMRS score of 15 or greater, (ii)
HAM-D 21-item score of 15 or greater or HAM-D suicide item score of 3 or
greater, (iii) CGI-S score of 3 or greater, (iv) hospitalization for treatment of
mood symptoms or (v) suicide or suicide attempt. Patients experiencing a
primary event were removed from further study follow-up.
Secondary outcome measures were time to a manic episode, time to a
depressive episode and time to premature discontinuation from the study
for any clinical reason (primary endpoint met, dose change in risperidone
or olanzapine study medication, new intervention, adverse event). Primary
outcome events were classiﬁed as manic or depressive based on the
CGI-BP, YMRS and HAM-D scores.

Sample size
The planned sample size for the trial was 540 patients (180 per group). This
sample size was based on two primary comparisons of the event
proportions (24-weeks vs 0-weeks groups and 52-weeks vs 0-week groups)
by 52 weeks, each at a two-sided signiﬁcance level of 0.025 (to ensure an
overall type I error rate less than 5%) with 80% power and allowing for a
25% drop-out rate. The assumed event proportions were 55% in the
0-week group and 38% (that is, absolute reduction of 17%) in each of the
other two groups.

Statistical analysis
All analyses were conducted on an intent-to-treat basis and included all
randomized patients. Kaplan–Meier cumulative incidence plots were used
to summarize the time to any mood episode by treatment group. For the
primary analysis, a Cox proportional hazards model with adjustment for
the antipsychotic drug and for the mood stabilizer drug was used to
compare the time to any mood episode across treatment groups. As a
sensitivity analysis, a mixed effects (frailty) Cox model with site entered as a
clustering variable was ﬁt to account for potential site effects. Patients who
did not experience the primary outcome were censored as of the time of
last follow-up visit.
Similar analyses were used to evaluate the time to a manic episode, and
the time to a depressive episode. When analyzing the time to a manic
(depressive) event, patients experiencing a depressive event (manic event)
were censored at the time of this event.
Changes in weight and laboratory parameters were calculated as the
difference between the measurements at baseline and at last follow-up;
if the measurement at last follow-up was missing, the most recently
observed value was used.

RESULTS
Patients and disposition
A total of 159 patients were randomized (52 to the 0-weeks group,
54 to the 24-weeks group and 53 to the 52-weeks group) into the
trial across 17 sites. The recruitment for the study was much
slower than anticipated and ultimately was stopped because of
expiration of funding.
Patient characteristics were well-balanced across the groups
except that the patients in the 0-weeks group had a higher
percentage of women, lower mean weight and lower percentage
with a history of or currently active psychiatric comorbidity
compared with the patients in the other two groups, while the
patients in the 24-weeks group had a lower percentage with
alcohol/substance abuse (Table 1). The disposition of patients is
summarized in Figure 1. A total of 34 (21%) patients discontinued
the study (8, 14 and 12 patients in the 0-weeks, 24-weeks and
52-weeks groups, respectively) for reasons other than meeting the
primary endpoint. The mean follow-up times were 18, 25 and
Molecular Psychiatry (2016), 1050 – 1056
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Table 1.

Baseline patient characteristics
0 weeks (N = 52a)

24 weeks (N = 54b)

52 weeks (N = 53c)

All (N = 159)

N (%)

N (%)

N (%)

N (%)

Male
Race
Caucasian
Asian
Black
Hispanic
Other
Alcohol/substance abuse comorbidity
Other psychiatric comorbidity

20 (38%)

28 (53%)

31 (58%)

45
3
2
0
2
23
9

40
4
4
4
1
17
15

40
3
6
1
3
22
17

Episode type
Manic
Mixed

43 (83%)
9 (17%)

45 (83%)
9 (17%)

43 (81%)
10 (19%)

Drug combination, n (%)
Lithium+Olanzapine
Lithium+Risperidone
Epival+Olanzapine
Epival+Risperidone

10
17
12
13

10
19
11
14

11
18
12
12

(86%)
(6%)
(4%)
(0%)
(4%)
(44%)
(17%)

(19%)
(33%)
(23%)
(25%)

Mean (s.d.)
Age (year)
Weight (kg)
Duration of bipolar disorder (year)
Lithium levels (mmol/L)
Valproate levels (μmol/L)
Olanazpine dose (mg)
Risperidone dose (mg)

38.96
71.58
10.56
0.79
469.19
10.11
2.08

(15.43)
(11.48)
(11.70)
(0.19)
(139.68)
(4.53)
(1.10)

(74%)
(8%)
(8%)
(8%)
(2%)
(31%)
(28%)

(19%)
(35%)
(20%)
(26%)

Mean (s.d.)
38.13
84.56
10.98
0.81
484.47
10.60
2.38

(75%)
(6%)
(11%)
(2%)
(6%)
(42%)
(32%)

(20%)
(34%)
(23%)
(23%)

Mean (s.d.)

(13.59)
(23.74)
(11.27)
(0.16)
(111.08)
(5.64)
(1.41)

36.66
84.42
11.71
0.79
504.25
9.57
2.45

(11.32)
(19.60)
(10.27)
(0.24)
(113.68)
(4.44)
(1.46)

79 (50%)
125
10
12
5
6
62
41

(79%)
(6%)
(8%)
(3%)
(4%)
(39%)
(26%)

131 (82%)
28 (18%)
31
54
35
39

(19%)
(34%)
(22%)
(25%)

Mean (s.d.)
37.91
80.33
11.08
0.80
485.47
10.08
2.31

(13.49)
(19.90)
(11.04)
(0.20)
(121.53)
(4.82)
(1.33)

Abbreviation: s.d., standard deviation. aOne patient missing weight; two patients missing lithium level. bOne patient missing age, gender, race; two patients
missing lithium level. cOne patient missing valproate level and duration of bipolar disorder.

Consented for participation
N=178

Screen failure N=11
Did not return for baseline, N=2
Ineligible at baseline, N=5
Withdraw consent, N=1

Enrollment

Randomized, eligible at baseline
N=159

“0” weeks group
N=52

24 weeks group
N=54

52 weeks group
N=53

Primary outcome event, N=39
Completed protocol, N=5

Primary outcome event, N=29
Completed protocol, N=11

Primary outcome event, N=29
Completed protocol, N=12

Discontinuations, N=8
Withdrew consent, N=4
Adverse event, N=1
Lost to follow-up, N=1
Protocol non-compliance, N=1
Deterioration in condition, N=1

Discontinuations, N=14
Withdrew consent, N=3
Adverse event, N=2
Lost to follow-up, N=2
Protocol non-compliance, N=7
Deterioration in condition, N=0

Discontinuations, N=12
Withdrew consent, N=4
Adverse event, N=4
Lost to follow-up, N=1
Protocol non-compliance, N=3
Deterioration in condition, N=0

Allocation

Follow-up

Figure 1.

Subject enrollment and disposition.
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Table 2.

Primary events by criterion and in antipsychotic sub-groups
Treatment group
0 weeks
N = 52

Total:
By study criteriona:
YMRS score of 15 or greater
HAM-D 21-item score of 15 or
greater
HAM-D suicide item score of 3 or
greater
CGI-S score of 3 or greater
Patient required hospitalization
Patient who made a suicide
attempt or committed suicide
Antipsychotic sub-groups
Olanzapine
Mania
Depression
Risperidone
Mania
Depression

24 weeks 52 weeks
N = 54
N = 53

39

29

29

10
16

5
13

7
14

4

5

2

38
8
0

27
1
0

29
3
0

N = 22
3
12
N = 30
11
13

N = 21
4
6
N = 33
2
17

N = 23
3
3
N = 30
4
19

Abbreviations: CGI-S, Clinical Global Impression Severity; HAM-D, Hamilton
Depression Rating Scale; YMRS, Young Mania Rating Scale. aPatients may
have met more than one criterion for a primary event.

24 weeks for the 0-weeks, 24-weeks and 52-weeks groups,
respectively.
Primary outcomes
There were 39 primary events (depression = 25, mania = 14) among
52 patients in the 0-weeks group, 29 events (depression = 23,
mania = 6) among 54 patients in the 24-weeks group and 29
(depression = 22, mania = 7) events among 53 patients in the
52-weeks group (Table 2). Kaplan–Meier cumulative incidence
curves (Figure 2a) suggested that the time to any mood episode
was longer in both 52-weeks and 24-weeks groups compared with
the 0-weeks group. However, the time to any mood episode was
similar between the 52-weeks and 24-weeks groups. In the
adjusted Cox analysis, the hazard ratio (HR) for time to any mood
episode was 0.53 for the 24-weeks group relative to the 0-weeks
group (95% conﬁdence interval (CI): 0.33, 0.86; P = 0.01) and 0.63
for the 52-weeks group relative to the 0-weeks group (95% CI:
0.39, 1.02; P = 0.06). The HR for the 52-weeks group relative to the
24-weeks group was 1.18 (95% CI: 0.71, 1.99; P = 0.52). On the basis
of the Kaplan–Meier curves, the estimated 52-week event rates
were 65%, 65% and 87% in the 52-weeks, 24-weeks and 0-weeks
groups, respectively. The results were negligibly different in the
mixed effects Cox model accounting for clustering by site.
Secondary outcomes
Across groups, a total of 27 patients met criteria for a manic event
and 70 for a depressive event. The time to a manic episode was
longer in patients randomized to the 24-weeks and the 52-weeks
groups compared with patients randomized to the 0-weeks group
(Figure 2b) and statistically signiﬁcant for the 24-weeks group
(HR: 0.30, 95% CI: 0.12, 0.80; P = 0.02) but not for the 52-weeks
group (HR: 0.43, 95% CI: 0.17, 1.09; P = 0.08). The time to a manic
episode was shorter in the 52-weeks group compared with the
24-weeks groups but the difference was not statistically signiﬁcant
(HR: 1.41, 95% CI: 0.47, 4.25, P = 0.54).
Although the time to a depressive episode was also longer in
the 24-weeks and 52-weeks groups compared with the 0-weeks
group (Figure 2c), this difference was not statistically signiﬁcant
© 2016 Macmillan Publishers Limited

for either group (HR for 24-weeks vs 0-weeks groups: 0.65;
95% CI: 0.37, 1.15, P = 0.14: HR for 52-weeks vs 0-weeks groups:
0.73; 95% CI: 0.41, 1.29, P = 0.28). In addition, the time to a
depressive episode was similar in the 52-weeks group compared
with the 24-weeks group (HR: 1.11; 95% CI: 0.62, 2.01, P = 0.72).
The time to discontinuation for any clinical reason was longer in
the 24-weeks and the 52-weeks groups compared with the
0-weeks group, but the effect was statistically signiﬁcant only for
the 24-weeks group (HR: 0.54, 95% CI: 0.34, 0.86, P = 0.01) but not
for the 52-weeks group (HR: 0.65, 95% CI: 0.41, 1.04, P = 0.07). The
time to discontinuation for any clinical reason was similar in the
52-weeks group compared with the 24-weeks group (HR: 1.22,
95% CI: 0.74, 1.99, P = 0.44).
Subgroup analysis. In the olanzapine subgroup, the time to any
mood episode was longer in both the 24-weeks and the 52-weeks
groups compared with the 0-weeks group, with the difference
reaching statistical signiﬁcance for the 52-week group (HR: 0.23,
95% CI: 0.09, 0.59, P = 0.003) but not for the 24-weeks group
(HR: 0.47, 95% CI: 0.21, 1.07, P = 0.07). The time to any mood
episode was longer but not statistically signiﬁcant in the 52-weeks
group compared with the 24-weeks group (HR: 0.48, 95% CI: 0.17;
1.32, P = 0.16).
In the risperidone subgroup, the time to any mood episode was
longer in the 24-weeks group relative to 0-weeks group but was
not statistically signiﬁcant (HR: 0.57, 95% CI: 0.31, 1.05, P = 0.07).
Surprisingly, the time to any mood episode in the 52-week group
was similar to that in the 0-weeks group (HR: 1.05, 95% CI: 0.59,
1.88, P = 0.86) and shorter than in the 24-weeks group (HR: 1.85,
95% CI: 1.00, 3.41; P = 0.05).
Adverse events
The only serious adverse event recorded was the single death
from pneumonia, which occurred in the 52-weeks group, and was
determined by the site investigator as being unrelated to the
study medication. Rates of other adverse events were similar
across the three groups (Table 3). The mean changes in the ESRS
total score, Parkinsonism+Dystonia subscale and Dyskinesia
subscale were similar across all three groups.
In terms of weight change, patients in the 52-weeks group
gained signiﬁcantly more weight (3.2 kg, P = 0.01) compared with
those in the 0-weeks group (lost 0.2 kg) and 24-weeks group
(lost 0.1 kg). Within the olanzapine subgroup, the weight changes
were a loss of 0.7 kg, a loss of 0.2 kg and a gain of 5.6 kg in the
0-week, 24-week and 52-week groups, respectively. The corresponding weight changes in the risperidone subgroup were a gain
of 0.3 kg, no change and a gain of 1.3 kg. Clinically signiﬁcant
weight gain (⩾7% or more of baseline weight) was more common
among patients in the 52-weeks group (25%) than in the 0-weeks
(12%) and 24-weeks (15%) groups. In the olanzapine subgroup,
more patients gained ⩾ 7% weight in the 52-weeks group (35%)
compared with the 0-weeks group (5%) or the 24-weeks group
(14%), while in the risperidone subgroup, these proportions were
more similar across the groups (17%, 15% and 17% in the 0-weeks,
24-weeks and 52-weeks groups, respectively). Average change in
glucose, cholesterol or triglycerides levels from baseline to last
follow-up were similar in all three groups whether including all
patients or in either antipsychotic subgroup.
DISCUSSION
This is the ﬁrst study to compare different durations of atypical
antipsychotic adjunctive therapy in the maintenance treatment of
bipolar I disorder after remission from an acute manic or mixed
episode. The most important ﬁndings of the study are: (i) The
time to relapse of any mood episode was signiﬁcantly longer in
the group that continued atypical antipsychotic adjunctive
Molecular Psychiatry (2016), 1050 – 1056
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Figure 2.

(a) Time to relapse of any mood episode. (b) Time to relapse of a manic episode. (c) Time to relapse of a depressive episode.

therapy for 24 weeks compared with the group that had their
atypical antipsychotic discontinued at study entry; (ii) There was a
trend for longer time to relapse of any mood episode in the
52-weeks group compared with the 0-weeks group; (iii) The time to
relapse of any mood episode was similar in the 52-weeks group
compared with the 24-weeks group; however, the sub-group
analysis showed discordance in effects of risperidone and olanzapine beyond 24 weeks. In addition, weight gain was signiﬁcantly
greater and more patients gained ⩾ 7% body weight with 52 weeks
of continued antipsychotic use compared with 24 weeks.
The ﬁndings of this study are highly clinically relevant and have
immediate transformational value for the management of bipolar
disorder. Although adjunctive atypical antipsychotic therapy was
beneﬁcial for 24 weeks after the remission of an acute manic
episode, the beneﬁts were not readily apparent beyond 24 weeks
as overall, there were no differences in relapse rates between the
Molecular Psychiatry (2016), 1050 – 1056

24-weeks and 52–weeks groups. Importantly, weight gain was
signiﬁcantly more common in the 52-weeks group compared with
the other two groups. Thus, these data suggest that adjunctive
atypical antipsychotic therapy beyond 24 weeks confers additional
adverse event burden without necessarily offering deﬁnitive
tangible clinical beneﬁt in efﬁcacy.
Although mania is the deﬁning feature of bipolar I disorder,
several studies suggest that depressive episodes and symptoms
outnumber manic/hypomanic episodes/symptoms by a ratio of
3:1 during the course of bipolar disorder.18 Consistent with this,
more patients in our study had depressive recurrences compared
with manic recurrences (70 vs 27 events, respectively). Despite
higher depressive recurrences, adjunctive therapy beneﬁt was
more apparent in preventing manic recurrences in the 24-weeks
(HR: 0.30) and 52-weeks (HR: 0.43) groups compared with the
0-weeks group than for preventing depressive recurrences
© 2016 Macmillan Publishers Limited
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Table 3. Adverse events and changes in Extrapyramidal Symptom
Rating Scale (ESRS) scores and metabolic parameters
Treatment group
0 weeks

Serious adverse events
Death
Non-serious adverse events
Cold/cold Symptoms
Headache
Weight gain
Fatigue/sedation/sleep
change
Muscle related injuries
Constipation
Menstrual irregularity/
cramps
Nausea
Diarrhea
Breast changes/
galactorrhea
Dry mouth
Dry skin/itch/rash
Extrapyramidal symptoms
Bloating/ﬂatulence
Dizziness
Hair loss
Impaired sexual function
Elevated glucose
Elevated prolactin level
Impaired vision
Increased appetite
Elevated lipids
Elevated liver function test
Increased dreaming
Tardive dyskinesia
Other
Change from baseline to
last visit
ESRS score
Total
Parkinsonism+Dystonia
subscale
Dyskinesia subscale
Metabolic parameters
Weight (kg)a
Glucose level (mmol l − 1)
Cholesterol level
(mmol l − 1)
Triglycerides (mmol l − 1)

24 weeks

52 weeks

N

%

N

%

0

0

0

0

1

2

5
9
4
4

10
17
8
8

6
3
6
5

11
6
11
9

7
6
7
4

13
11
13
8

4
3
2

8
6
4

3
5
2

6
9
4

5
1
6

9
2
11

3
1
1

6
2
2

4
4
3

7
7
6

1
2
1

2
4
2

2
1
1
1
0
1
0
0
0
0
0
0
0
0
1
6

4
2
2
2
0
2
0
0
0
0
0
0
0
0
2
12

1
2
2
1
2
0
3
1
1
2
1
1
1
1
0
3

2
4
4
2
4
0
6
2
2
4
2
2
2
2
0
6

1
1
1
1
1
2
0
1
1
0
1
0
0
0
0
3

2
2
2
2
2
4
0
2
2
0
2
0
0
0
0
6

N

%

Mean

s.d.

Mean

s.d. Mean s.d.

1.3
− 0.7

8.9
3.2

2.3
− 0.2

8.3
1.8

0.02 0.32

2.3
0.0

0.00 0.00 0.02

9.8
4.2
0.14

− 0.2
0.7
− 0.2

4.8
3.7
1

− 0.1 6.8
− 0.01 0.7
− 0.3 0.7

3.2
0.1
0.02

6.8
0.9
1.0

0.3

1.6

−0.02 0.7

0.1

1.8

Abbreviation: s.d., standard deviation. aP-value = 0.01 for the difference
between the 52-weeks and 0-weeks groups and between the 52-weeks
and 24-weeks groups.

(HR: 0.65 for the 24 weeks group and HR: 0.73 for the 52 weeks
group). These data are consistent with the clinical observation and
ﬁndings from other studies which suggest that many atypical
antipsychotics are more effective in preventing manic than
depressive recurrences.8,9,19,20
This study was not adequately powered for analysis of the
antipsychotic subgroups, but several ﬁndings warrant discussion.
The prophylactic effect of risperidone was apparent only for mania
whereas for olanzapine, the beneﬁt was seen mainly in preventing
© 2016 Macmillan Publishers Limited

depression (Table 2). These ﬁndings are broadly consistent with
previous studies21,22 although the lack of effect of olanzapine in
preventing mania is surprising. This might be because many of the
patients in the olanzapine 0-weeks group had a depressive event,
and thus left fewer patients at risk for mania. The HR for the time
to any mood episode comparing the 24-weeks group with the
0-weeks group were similar for both olanzapine and risperidone.
Hence, the ﬁnding of beneﬁt of 24 weeks of therapy appears
robust and applicable to both antipsychotics. In contrast, when
comparing the 52-weeks group with the 24-weeks group, the
results were discordant between the two antipsychotics. In the
risperidone subgroup, the risk of relapse increased with a near
doubling of the HR. Even if this result is a false signal and
continued use of risperidone beyond 24 weeks does not truly
increase the risk of relapse, it remains unlikely that any beneﬁt
exists. In the olanzapine subgroup, the risk of relapse decreased
with the HR roughly halved though not statistically signiﬁcant.
This result could be because of inadequate sample size. However,
this reduction in risk of relapse was accompanied by a 20%
increase in risk of weight gain by at least 7% and an average
weight gain of nearly 6 kg. Given that the weight gain is a
predictor of poor clinical outcomes in bipolar disorder,23,24 the
potential clinical beneﬁt of continuing olanzapine beyond
24 weeks needs to be balanced against the risks of weight-gainassociated morbidity and mortality.
The incidence of adverse events was relatively low and few
patients dropped out of the study because of adverse events.
There were no signiﬁcant differences in rates of adverse events,
metabolic parameters or ESRS scale scores between the three
groups. This may be because of the enriched design in which only
those patients who responded and tolerated these medications
were eligible to enter the trial. Despite such enrichment in design,
patients in the 52-weeks group gained considerably more weight
and more patients in this group had clinically signiﬁcant weight
gain, and in particular, those who had received olanzapine
adjunctive therapy. This suggests that weight gain with olanzapine may continue beyond 24 weeks.
This study has several strengths including the use of a stratiﬁed
randomized double-blind design, that it recruited ‘real world’
patients with and without comorbidity, and allowed routine
clinical management including psychoeducation and counseling
as clinically indicated. However, some limitations must also be
considered. First, this study included only risperidone and
olanzapine; hence, the ﬁndings of this study may not be
generalizable to all atypical antipsychotics. Nevertheless, the
ﬁndings of this study are consistent with other maintenance
studies showing that the efﬁcacy in prevention of relapse is most
apparent in the ﬁrst 6 months. Second, owing to recruitment
challenges, the ﬁnal sample size was smaller than originally
planned. Larger sample sizes would have yielded more precise
assessments of the differences between the 24-weeks and
52-weeks groups in the olanzapine and risperidone subgroups
and provided more deﬁnitive conclusions as to whether the
discordant ﬁndings truly reﬂect a reduced risk of relapse with
continued olanzapine use, an increased risk with continued
risperidone use, or both. Third, comparisons of adverse event
rates and change in outcome measures may be impacted by
differences in the average length of follow-up across treatment
groups. However, mean follow-up time in the 24-weeks and
52-weeks arms were similar and so do not explain the weight gain
differences between these two groups. Last, clinicians were
allowed to provide adjunctive psychological treatments as
clinically appropriate. Although differences in types and duration
of psychological treatments might have contributed to differences
in efﬁcacy, this is also a strength of this study in that it mirrored
real world clinical practice.
In conclusion, the results of this study suggest that patients with
bipolar I disorder who recently remitted from an acute manic
Molecular Psychiatry (2016), 1050 – 1056
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episode with adjunctive risperidone or olanzapine therapy are less
likely to have a recurrence if these medications are continued for
24 weeks vs discontinuing soon after remission of mania. However,
beneﬁts beyond 24 weeks are not apparent; subgroup results
suggest continued risperidone use provides no beneﬁt and although
it remains unclear whether continued olanzapine use reduces the risk
of recurrence, the potential beneﬁt should be weighed against a
concomitant increased risk of weight gain. Given the clinical
signiﬁcance of these ﬁndings, future studies should use the similar
design to examine the applicability of these ﬁndings to other atypical
antipsychotics that have less metabolic burden liability.
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